galantamine has been researched along with Basal Ganglia Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A | 1 |
| Herrmann, N; Lanctôt, KL; Thompson, S | 1 |
1 review(s) available for galantamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseases; Cholinesterase Inhibitors; Clinical Trials as Topic; Comorbidity; Donepezil; Double-Blind Method; Drug Evaluation; Drug Interactions; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Institutionalization; Longitudinal Studies; Male; Memantine; Meta-Analysis as Topic; Mice; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Single-Blind Method; Sleep Wake Disorders; Treatment Outcome | 2004 |
1 other study(ies) available for galantamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Interactions; Galantamine; Haloperidol; Hypokinesia; Indans; Male; Mice, Inbred Strains; Nootropic Agents; Piperidines; Receptor, Serotonin, 5-HT1A; Receptors, Muscarinic; Serotonin Agents | 2015 |